爾康製藥(300267.SZ):2022年度擬使用不超10億元閒置自有資金進行現金管理
格隆匯11月19日丨爾康製藥(300267.SZ)公佈,公司於2021年11月19日召開第四屆董事會第十八次會議、第四屆監事會第十八次會議,審議通過了《關於2022年度使用閒置自有資金進行現金管理的議案》,為提高公司資金使用效率,合理利用閒置自有資金,在保證日常經營資金需求和資金安全的前提下,公司2022年度擬使用不超過10億元人民幣的閒置自有資金進行現金管理。在上述額度及期限內,資金可以滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.